Imatinib Accord (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By inhibiting these enzymes, the drug stops downstream signaling that promotes uncontrolled cell division, leading to reduced proliferation and increased apoptosis of malignant cells that rely on these pathways.

The appropriate dose of Imatinib Accord is determined by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s written order.

Safety data for imatinib in pregnancy and lactation are limited. The drug may pose risks to the fetus or infant, and its use is generally avoided unless the potential benefit justifies the risk. Women of child‑bearing potential should discuss contraception and treatment options with their healthcare provider.

To request Imatinib Accord, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib is the first‑generation BCR‑ABL inhibitor and is often compared with second‑generation agents such as dasatinib or nilotinib. While newer TKIs may offer higher potency and activity against certain resistant mutations, imatinib remains a standard of care for many patients due to its well‑characterized efficacy, safety profile and extensive clinical experience.

Imatinib Accord should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Imatinib Accord is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber. Swallow tablets whole; do not crush or chew unless the formulation specifically permits it.

Serious adverse events include hepatotoxicity (elevated liver enzymes or liver injury), severe neutropenia or thrombocytopenia (dangerously low blood cell counts), and cardiac complications such as heart failure or pulmonary hypertension. Patients should report symptoms like jaundice, persistent fever, unusual bruising, shortness of breath or swelling to their healthcare provider promptly.

Imatinib should be avoided in individuals with known hypersensitivity to imatinib or any of its excipients. It is also contraindicated in patients with severe hepatic impairment or uncontrolled cardiac disease. Clinicians must assess each patient’s medical history before initiating therapy.